葫芦娃因内控缺陷被ST，多项财务问题引审计疑云

Core Viewpoint - Hainan Huluwa Pharmaceutical Group Co., Ltd. announced that its stock will be subject to risk warnings due to an audit report indicating internal control issues, leading to a change in stock abbreviation and a reduction in daily price fluctuation limits [1][4]. Group 1: Stock Trading and Risk Warning - The company's stock will be traded under the abbreviation "ST Huluwa" starting April 30, with the stock code remaining "605199" [1]. - The daily price fluctuation limit will be adjusted from 10% to 5% [1]. Group 2: Financial Reporting Issues - The risk warning stems from the 2023 annual report, which revealed issues such as premature revenue recognition and unusual sales prices, resulting in inaccurate financial data disclosures [4]. - The audit report from Lixin Certified Public Accountants indicated that the company had not provided complete financial materials related to the restatement of its 2023 financial statements, leading to a qualified opinion on the 2024 financial statements [4]. Group 3: Additional Concerns - Lixin's report disclosed that the controlling shareholder provided financial support to customers through personal bank accounts, raising concerns about the company's receivables [6]. - Some of the top 10 customers by accounts receivable showed no payments or minimal payments after the reporting period [6]. - The company purchased 12 R&D projects from Hainan Zhongwang Medical Technology Development Co., Ltd. for over 60 million yuan, with familial ties between the legal representative of Zhongwang and one of Huluwa's actual controllers, raising potential conflicts of interest [6]. - Huluwa has committed to taking corrective measures to address internal control deficiencies and improve financial compliance [6].